In March 2025, the company declared new strategies for the immediate-to-consumer supplying of its Wegovy weight loss drug. The company set up a completely new pharmacy, called NovoCare, which would cost prospects $499 each month for access to the drug, below 50 percent the expense of the drug by means of other pharmaceutical distribution networks.[